Assignee
NOVARTIS PHARMACEUTICALS CORP
US·10 granted patents·11 pending applications·346 citations·filing 1990–2024
Top patents by PatentIndex Score
21 records- 0197US5753675AQuinoline analogs of mevalonolactone and derivatives thereofNOVARTIS PHARMACEUTICALS CORP·Filed 1990·Granted May 19, 1998·179 cites·10 claims
- 0291US2025339395A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2024·Application pending·0 cites
- 0390US6338407B2Child resistant medication packageNOVARTIS PHARMACEUTICALS CORP·Filed 2001·Granted Jan 15, 2002·86 cites·6 claims
- 0486US11028077B2Crystalline pharmaceutical and methods of preparation and use thereofNOVARTIS PHARMACEUTICALS CORP·Filed 2016·Granted Jun 8, 2021·3 cites·17 claims
- 0585US2023331711A1Crystalline pharmaceutical and methods of preparation and use thereofNOVARTIS PHARMACEUTICALS CORP·Filed 2023·Application pending·0 cites
- 0684US11642329B2Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2022·Granted May 9, 2023·0 cites·2 claims
- 0783US2022257551A1Amorphous solid form of compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2022·Application pending·0 cites
- 0882US10906892B2LFA-1 inhibitor and methods of preparation and polymorph thereofNOVARTIS PHARMACEUTICALS CORP·Filed 2019·Granted Feb 2, 2021·1 cites·15 claims
- 0982US7371865B2Process for the manufacture of HMG-CoA reductase inhibitorsNOVARTIS PHARMACEUTICALS CORP·Filed 2003·Granted May 13, 2008·19 cites·12 claims
- 1081US11096918B2Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2019·Granted Aug 24, 2021·0 cites·2 claims
- 1179US2021361610A1Compounds containing s-n-valeryl-n-{[2'-(1h-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cationsNOVARTIS PHARMACEUTICALS CORP·Filed 2021·Application pending·0 cites
- 1276US2022073500A1Crystalline pharmaceutical and methods of preparation and use thereofNOVARTIS PHARMACEUTICALS CORP·Filed 2021·Application pending·0 cites
- 1375US6230894B1Child resistant package and method of dispensing medicationNOVARTIS PHARMACEUTICALS CORP·Filed 1998·Granted May 15, 2001·53 cites·4 claims
- 1475US2021145824A1Modulators of cellular adhesionNOVARTIS PHARMACEUTICALS CORP·Filed 2020·Application pending·0 cites
- 1561US2016303092A1Treatment of solid tumors with rapamycin derivativesNOVARTIS PHARMACEUTICALS CORP·Filed 2016·Application pending·0 cites
- 1656US8052987B2Method of administering bisphosphonatesNOVARTIS PHARMACEUTICALS CORP·Filed 2001·Granted Nov 8, 2011·2 cites·9 claims
- 1753US2022313663A1Eltrombopag dosing regimenNOVARTIS PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 1842US6211384B1Methods for the acylation of amine compoundsNOVARTIS PHARMACEUTICALS CORP·Filed 1999·Granted Apr 3, 2001·3 cites·14 claims
- 1938US2007293482A1Process for Preparing BenzodiazepinesNOVARTIS PHARMACEUTICALS CORP·Filed 2005·Application pending·0 cites
- 2034US2007185096A1Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion proteinNOVARTIS PHARMACEUTICALS CORP·Filed 2005·Application pending·0 cites
- 2133US2008139536A1Benzodiazepines for Treating or Preventing Rsv InfectionNOVARTIS PHARMACEUTICALS CORP·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NOVARTIS PHARMACEUTICALS CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →